Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 1;16(12):e0259909.
doi: 10.1371/journal.pone.0259909. eCollection 2021.

Towards risk stratification and prediction of disease severity and mortality in COVID-19: Next generation metabolomics for the measurement of host response to COVID-19 infection

Paulo D'Amora  1   2   3 , Ismael Dale C G Silva  1   4 , Maria Auxiliadora Budib  5 , Ricardo Ayache  5 , Rafaela Moraes Siufi Silva  5 , Fabricio Colacino Silva  5 , Robson Mateus Appel  5 , Saturnino Sarat Júnior  5 , Henrique Budib Dorsa Pontes  5 , Ana Carolina Alvarenga  5 , Emilli Carvalho Arima  5 , Wellington Galhano Martins  5 , Nakal Laurenço F Silva  5 , Ricardo Sobhie Diaz  6 , Marcia B Salzgeber  1 , Anton M Palma  7 , Steven S Evans  2   3   4 , Robert A Nagourney  2   3   4   8   9
Affiliations

Towards risk stratification and prediction of disease severity and mortality in COVID-19: Next generation metabolomics for the measurement of host response to COVID-19 infection

Paulo D'Amora et al. PLoS One. .

Abstract

This study investigated the association between COVID-19 infection and host metabolic signatures as prognostic markers for disease severity and mortality. We enrolled 82 patients with RT-PCR confirmed COVID-19 infection who were classified as mild, moderate, or severe/critical based upon their WHO clinical severity score and compared their results with 31 healthy volunteers. Data on demographics, comorbidities and clinical/laboratory characteristics were obtained from medical records. Peripheral blood samples were collected at the time of clinical evaluation or admission and tested by quantitative mass spectrometry to characterize metabolic profiles using selected metabolites. The findings in COVID-19 (+) patients reveal changes in the concentrations of glutamate, valeryl-carnitine, and the ratios of Kynurenine/Tryptophan (Kyn/Trp) to Citrulline/Ornithine (Cit/Orn). The observed changes may serve as predictors of disease severity with a (Kyn/Trp)/(Cit/Orn) Receiver Operator Curve (ROC) AUC = 0.95. Additional metabolite measures further characterized those likely to develop severe complications of their disease, suggesting that underlying immune signatures (Kyn/Trp), glutaminolysis (Glutamate), urea cycle abnormalities (Cit/Orn) and alterations in organic acid metabolism (C5) can be applied to identify individuals at the highest risk of morbidity and mortality from COVID-19 infection. We conclude that host metabolic factors, measured by plasma based biochemical signatures, could prove to be important determinants of Covid-19 severity with implications for prognosis, risk stratification and clinical management.

PubMed Disclaimer

Conflict of interest statement

R.S. Diaz, M.A. Budib, R. Ayache, R.M.S. Silva, F.C. Silva, S.S. Júnior, H.B.D. Pontes, A.C. Alvarenga, E.C. Arima, W.G. Martins, N.L.F. Silva, M.B. Salzgeber and A.M. Palma have no conflicts of interest to declare. P. D’Amora (consultation: Metabolomycs, Inc.; intellectual property rights (patent pending) Metabolomycs, Inc.; stockholder: Metabolomycs, Inc.). S.S. Evans (stockholder: Metabolomycs, Inc.). I.D.C.G. da Silva (consultation, Metabolomycs, Inc.; intellectual property (patent pending) Metabolomycs, Inc.; board director Metabolomycs, Inc.; stockholder: Metabolomycs, Inc.). R.A. Nagourney (intellectual property rights (patent pending) Metabolomycs, Inc.; board director: Nagourney Institute, board director Metabolomycs, Inc.; stockholder: Metabolomycs, Inc.). Robson Mateus Appel (RMA) was reimbursed for patient registration and sample collection costs by Metabolomycs, Inc. Dr. D’Amora and Dr da Silva of UNIFESP, receive consulting fees from Metabolomycs, Inc. for their cancer-related metabolomic research. We certify that the submission is original work and is not under review at any other publication.

Figures

Fig 1
Fig 1. Flowchart illustrating workflow and data processing.
Individual metabolite absolute concentrations measured by targeted mass spectrometry (MS/MS) transmitted in.csv data-files were log transformed for normalization and then uploaded into MetaboAnalyst 5.0 bio-informatic data analytic platform. Univariate (t-test, ANOVA), multivariate (PCA, PLS-DA, Heatmaps, Multivariate ROC Curve Analysis) and correlation coefficients (Pearson r) then applied to identify metabolites and ratios associated with COVID-19.
Fig 2
Fig 2
(A, B) reflect unsupervised clustering analysis using the most discriminating ratios that segregate controls (n = 31) from COVID-19 (+) patients (n = 77). The average accuracy based on 100 cross validations is 0.95 with an ROC AUC = 0.975 (95% CI 0.889–0.999) and permutation test statistic: p<0.0001.
Fig 3
Fig 3
(A, B) provide base line predictions separating mild from moderate/severe using multivariate ROC Curve analysis applying the ratios obtained from the training set (Fig 2A and 2B): [(Glu/PC ae C42:1)/Taurine] and [IDO/(Cit/Orn)]/(PC ae C36:4). The average accuracy based on 100 cross validations is 0.90, Permutation Test (x500) statistics = p< 7.10e-05.
Fig 4
Fig 4. Heatmap of unsupervised clustering analysis using 30 most discriminating metabolites and ratios comparing mild (red) vs moderate/severe (green) Covid 19 outcomes.
Fig 5
Fig 5. Ratio of immune dysfunction reflected by indole oxygenase activity (Kyn/Trp) over liver dysfunction reflected by ornithine transcarbamylase (Cit/Orn) discriminates patients with mild vs moderate/severe outcomes.
100-fold Cross Validation = 0.82, Predictive Accuracy (100 permutations) p = 1.00E-03.
Fig 6
Fig 6
(A-D). Comparison of immune signatures for Covid 19 vs. HIV using immune IDO (Kyn/Trp) ratio divided by the inflammatory markers (lyso PC a 18:2 and 18:0) correlates Covid 19 severity with HIV progression.
Fig 7
Fig 7
(A, B). Pearson Moment correlations of IDO activity (Kyn/Trp) and Ornithine transcarbamylase activity (Cit/Orn) for disease severity comparing controls, mild, moderate, and severe Covid patients.
Fig 8
Fig 8
(A, B). Glutamate and Valeryl-carnitine (C5) concentrations comparing controls (red) n = 36 to Covid 19 patients (green) n = 77 provide ROC AUC = 0.85 (95% CI 0.764–0.92) and AUC = 0.799 (95% CI 0.715–0.875) respectively.
See this image and copyright information in PMC

References

    1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al.. A new coronavirus associated with human respiratory disease in China. Nature. 2020. Mar;579(7798):265–269. Epub 2020 Feb 3. Erratum in: Nature. 2020 Apr;580(7803):E7. doi: 10.1038/s41586-020-2008-3 . - DOI - PMC - PubMed
    1. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020. May;39(5):405–407. Epub 2020 Mar 20. doi: 10.1016/j.healun.2020.03.012 . - DOI - PMC - PubMed
    1. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al.. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020. Dec;13(12):1833–1839. Epub 2020 Aug 4. doi: 10.1016/j.jiph.2020.07.014 . - DOI - PMC - PubMed
    1. Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol. 2020. Jun;16(6):297–298. doi: 10.1038/s41574-020-0353-9 . - DOI - PMC - PubMed
    1. Scarpellini B, Zanoni M, Sucupira MC, Truong HM, Janini LM, da Silva ID, et al.. Correction: Plasma Metabolomics Biosignature According to HIV Stage of Infection, Pace of Disease Progression, Viremia Level and Immunological Response to Treatment. PLoS One. 2017. Feb 24;12(2):e0173164. Erratum for: PLoS One. 2016 Dec 12;11(12):e0161920. doi: 10.1371/journal.pone.0173164 . - DOI - PMC - PubMed

Publication types

MeSH terms